Setmelanotide for the Treatment of Acquired Hypothalamic Obesity

Summary

A New England Journal of Medicine publication presents setmelanotide as a treatment option for acquired hypothalamic obesity. The article appears to be a clinical review or research report rather than announcing new trial results or regulatory actions.